Literature DB >> 8773958

Pharmacokinetics, tissue distribution, and expression efficiency of plasmid [33P]DNA following intravenous administration of DNA/cationic lipid complexes in mice: use of a novel radionuclide approach.

G Osaka1, K Carey, A Cuthbertson, P Godowski, T Patapoff, A Ryan, T Gadek, J Mordenti.   

Abstract

The pharmacokinetics, tissue distribution, and efficacy of a systemic gene transfer method were examined in male BALB/c mice (6-8 weeks old) using 33P-labeled plasmid DNA for luciferase. The DNA was delivered via tail vein injection in saline ([33P]DNA) or in a cationic lipid formulation ([33P]DNA/lipid). One group of mice received approximately equal to 1-3 microCi (45 micrograms of DNA) of either formulation, and mice were euthanized at 2 and 20 min, and 1 and 24 h postdose (2 mice/time point). Blood and plasma radioactivity were quantified, and whole body autoradiographic (WBAR) images were obtained from 20-microns whole body sections. A tissue distribution (TD) study was conducted in a second group of mice, which received approximately equal to 4-6 microCi (45-60 micrograms of DNA) of [33P]DNA/lipid. Mice were euthanized at 1.5 h (1 mouse; [33P]DNA/lipid) or 24 h (2 mice/ group), and organ radioactivity and luciferase expression were measured in lung, liver, kidney, spleen thymus, and parotid salivary gland by direct quantitation methods. Microautoradiography (MAR) was performed on a third group of mice (n = 2), which received 3 microCi (45 micrograms of DNA) of [33P]DNA/lipid and were euthanized at 24 h postdose. For WBAR, the [33P]DNA/lipid tissue distribution (% dose equiv/g) at 2 min was lung >> liver > spleen (red pulp) > kidney (cortex); at 24 h the ranking was spleen (red pulp) > liver > lung, kidney (cortex). The [33P]DNA organ distribution observed at 2 min was liver >> spleen (red pulp) > lung, blood > kidney (cortex); at 24 h the ranking was liver, spleen (red pulp) > kidney (cortex) > lung, blood. High levels of radioactivity in bone (cortical, marrow, growth plate) in both groups may represent uptake of the 33P-labeled test articles by the cellular component of the bone marrow, particularly macrophages, as well as deposition of [33P]phosphate in the bone matrix following metabolism of the [33P]DNA. In the luciferase component of the study, no expression was observed in the [33P]DNA group at 24 h. The [33P]- DNA/lip group exhibited expression as early as 1.5 h in the lung; at 24 h, expression was seen in all the organs examined. Microautoradiography of 24-h tissue samples revealed radioactivity in hepatic Kupffer cells, reticuloendothelial system cells in the marginal zone of the spleen, and diffusely along alveolar septae with scattered accumulations in alveolar macrophages. The results of the WBAR, TD, MAR, and luciferase assay show that the use of cationic lipids significantly altered the biodistribution and resulting expression of the DNA plasmid. Further, 33P (0.25 MeV beta, half-life = 25 days) was shown to be an excellent radionuclide for quantitative WBA and MAR, providing sharp images with less personal hazard and greater ease of handling than 32P (1.71 MeV beta, half-life = 14.3 days).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8773958     DOI: 10.1021/js9504494

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  19 in total

1.  Kinetic modeling of plasmid DNA degradation in rat plasma.

Authors:  B E Houk; G Hochhaus; J A Hughes
Journal:  AAPS PharmSci       Date:  1999

Review 2.  Gene therapy: a pharmacokinetic/pharmacodynamic modelling overview.

Authors:  Zinnia P Parra-Guillén; Gloria González-Aseguinolaza; Pedro Berraondo; Iñaki F Trocóniz
Journal:  Pharm Res       Date:  2010-04-13       Impact factor: 4.200

Review 3.  Drug transport to brain with targeted liposomes.

Authors:  Anita Schnyder; Jörg Huwyler
Journal:  NeuroRx       Date:  2005-01

Review 4.  Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy.

Authors:  William M Pardridge
Journal:  NeuroRx       Date:  2005-01

5.  Ligands located within a cholesterol domain enhance gene delivery to the target tissue.

Authors:  Long Xu; Jamie Betker; Hao Yin; Thomas J Anchordoquy
Journal:  J Control Release       Date:  2012-03-09       Impact factor: 9.776

6.  Pharmacokinetics and risk evaluation of DNA vaccine against Schistosoma japonicum.

Authors:  Hai-Feng Liu; Wei Li; Ming-Bo Lu; Long-Jiang Yu
Journal:  Parasitol Res       Date:  2012-09-19       Impact factor: 2.289

7.  Plasmid-based gene transfer ameliorates visceral storage in a mouse model of Sandhoff disease.

Authors:  Akira Yamaguchi; Kayoko Katsuyama; Kyoko Suzuki; Kenji Kosaka; Ichiro Aoki; Shoji Yamanaka
Journal:  J Mol Med (Berl)       Date:  2003-02-12       Impact factor: 4.599

8.  Brain-specific expression of an exogenous gene after i.v. administration.

Authors:  N Shi; Y Zhang; C Zhu; R J Boado; W M Pardridge
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-09       Impact factor: 11.205

9.  Distribution and expression of recombinant plasmid encoding chicken interleukin-2.

Authors:  Z Q You; L Yu; C Z Zhang; L Li; M J Lu; Z J Mao; Y Liu; W Y Chu
Journal:  Vet Res Commun       Date:  2006-12-20       Impact factor: 2.459

10.  Cyclic RGD-targeting of reversibly stabilized DNA nanoparticles enhances cell uptake and transfection in vitro.

Authors:  Qing-Hui Zhou; Ye-Zi You; Chao Wu; Yi Huang; David Oupický
Journal:  J Drug Target       Date:  2009-06       Impact factor: 5.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.